Inactive Instrument

IGI LABORIGI Stock NYSE

Stocks

End-of-day quote NYSE Other stock markets
- ^USD	-

22-07-26	Teligent, Inc. Went Out of Business	CI
22-07-15	Second Amended Liquidation Plan Approved for Teligent, Inc.	CI

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

News in other languages: IGI LABORIGI

18-10-01	ENQUETE CREDIT : Les gérants se montrent plus optimistes
18-09-03	ENQUETE CREDIT : Les gérants abordent la rentrée avec prudence
18-07-02	ENQUETE CREDIT : Les gérants restent sur leurs gardes
17-05-16	BONDS : Le marché primaire du crédit en euro redémarre en trombe
17-03-28	Les émetteurs français et allemands dynamisent le marché du crédit

More news

Managers and Directors: IGI LABORIGI

Manager	Title	Age	Since
Joseph Benesch AUD	Comptroller/Controller/Auditor	59	2021-05-31
Vladimir Kasparov PRN	Corporate Officer/Principal	-	2021-10-13
William Graham PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Carole Ben-Maimon BRD	Director/Board Member	67	2016-03-28
Thomas Sabatino BRD	Director/Board Member	67	2017-08-31
Bradley Eric Scher BRD	Director/Board Member	65	2021-10-13

More insiders

Teligent, Inc. is a generic pharmaceutical company. The Company is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. It also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. The Company's portfolio of hospital-based sterile injectable products, including cephalosporins, Cefotan (Cefotetan for Injection), Fortaz (Ceftazidime) and Zinacef (Cefuroxime Sodium).

Employees

Sector

More about the company

22-07-26	Teligent, Inc. Went Out of Business	CI
22-07-15	Second Amended Liquidation Plan Approved for Teligent, Inc.	CI
22-05-25	Second Motion for Exclusivity Period Extension Approved For Teligent, Inc.	CI
22-05-24	Second Amended Joint Liquidation Plan Filed by Teligent, Inc.	CI
22-04-29	First Amended Disclosure Statement Approved for Teligent, Inc.	CI
22-04-27	First Amended Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	CI
22-04-08	Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	CI
22-02-28	First Motion for Exclusivity Period Extension Approved For Teligent, Inc.	CI
22-02-22	Motion for Case Conversion Filed by Teligent, Inc.	CI
22-02-09	First Motion for Exclusivity Period Extension Filed by Teligent, Inc.	CI
22-02-03	Hikma Pharmaceuticals Closes $46 Million Purchase of Teligent's Canadian Assets	MT
22-02-02	Pharmaceutical Associates, Inc. completed the acquisition of Generic and Branded US Marketing Authorizations of Teligent, Inc. (OTCPK:TLGT.Q).	CI
22-02-02	Hikma Pharmaceuticals PLC completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).	CI

22-08-05	Hikma's diversified business delivers resilient H1 performance	AQ
22-01-18	Hikma expands into Canada with acquisition of Teligent sterile injectable assets	AQ
21-11-16	What We're Reading This Week [November 15, 2021]	AQ
21-10-15	Teligent : Company is arranging $12 million debtor-in-possession financing from its senior secured lenders and access to its cash collateral on a consensual basis - Form 8-K	PU
21-10-15	TELIGENT, INC. : Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers, Regulation (form 8-K)	AQ

IGI LABORIGI Stock NYSE

Stocks

Latest news : IGI LABORIGI

Press Releases: IGI LABORIGI

News in other languages: IGI LABORIGI

Managers and Directors: IGI LABORIGI

Company Profile